Statement of Deviation and/or Variation for the half year ended on March 31, 2025 is attached herewith.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Hamps Bio Ltd has filed a compliance statement under SEBI Regulation 32 confirming there is NO deviation or variation in the use of funds raised from its Initial Public Offering (IPO) in December 2024. The company raised approximately Rs. 22.20 Crores through the IPO (held on December 20, 2024). As per the disclosed allocations, Rs. 208 lakhs has been utilized towards purchase of machinery, Rs. 17.14 lakhs for brand visibility and awareness, Rs. 94.20 lakhs (fully utilized) for general corporate purposes, and Rs. 119 lakhs (fully utilized) towards issue expenses. The Audit Committee reviewed the statement and had no comments, and the auditors also raised no comments. No monitoring agency was appointed for this issue.
This is a routine SEBI compliance filing and carries no negative signal — the company is using IPO proceeds as originally promised to shareholders. For investors, this confirms proper fund utilization and good governance, though it is largely a procedural disclosure with no direct impact on stock price or business outlook.